VTAK Stock Overview
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Catheter Precision, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$1.55 |
| 52 Week Low | US$0.34 |
| Beta | 0 |
| 1 Month Change | -13.12% |
| 3 Month Change | 12.75% |
| 1 Year Change | -69.23% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| VTAK | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -9.8% | -4.1% | -3.7% |
| 1Y | -69.2% | -2.2% | 20.5% |
Return vs Industry: VTAK underperformed the US Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: VTAK underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| VTAK volatility | |
|---|---|
| VTAK Average Weekly Movement | 18.3% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VTAK's share price has been volatile over the past 3 months.
Volatility Over Time: VTAK's weekly volatility has increased from 12% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 14 | David Jenkins | www.catheterprecision.com |
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company’s lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device.
Catheter Precision, Inc. Fundamentals Summary
| VTAK fundamental statistics | |
|---|---|
| Market cap | US$3.48m |
| Earnings (TTM) | -US$71.37m |
| Revenue (TTM) | US$442.00k |
7.6x
P/S Ratio0.0x
P/E RatioIs VTAK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTAK income statement (TTM) | |
|---|---|
| Revenue | US$442.00k |
| Cost of Revenue | US$30.00k |
| Gross Profit | US$412.00k |
| Other Expenses | US$71.78m |
| Earnings | -US$71.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.42 |
| Gross Margin | 93.21% |
| Net Profit Margin | -16,147.51% |
| Debt/Equity Ratio | 0.9% |
How did VTAK perform over the long term?
See historical performance and comparison